invokana fda warning alert
The FDA recently added warnings about Invokana ketoacidosis (DKA) and Invokana kidney damage. Due to the manufacturer's failure to properly protect consumers, lawyers have initiated a national invokana lawsuit on behalf of those injured. Read more about the drug and your rights below. If you have experienced kidney damage or ketoacidosis after using Invokana, call us to speak directly with a lawyer today.
What is Invokana and Why is it Prescribed?
Invokana works by blocking the SGLT2, or subtype 2 sodium-glucose transport protein (SGLT2). This protein causes around 90% of the kidneys' absorption of glucose. Without it, a substantial amount of sugar is expelled through the urine rather than being retained in the blood.
Other effects of this include a lowering of blood pressure and weight loss in some patients. Certain patients with type 1 diabetes have also reported lower blood sugar levels from Invokana, leading to off-label prescriptions for these purposes.
Invokana is only approved for type 2 diabetes. It was approved by the European Medicines Agency in 2011 and by the United States FDA in March of 2013. It sold over $500 million in 2014 and is on pace to break $1 billion in sales for 2015.
Type 2 diabetes has grown to the 7th leading cause of death in the United States. It can cause severe side effects like heart disease, blindness, kidney disease, stroke, hypertension and nerve damage if not treated correctly.